EGFR and non-small cell lung carcinoma: The studies show that the advanced NSCLC patients receiving chemotherapy treatment (including pemetrexed, docetaxel, gemcitabine, cisplatin, and carboplatin) intercalated with targeted therapy (EGFR-TKI: erlotinib) has significantly prolonged PFS and is in favor of overall survival [72,73,74].